Zevra Therapeutics (ZVRA) 10-K 7 Mar 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 03, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0001434647
Entity Registrant Name	ZEVRA THERAPEUTICS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-36913
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5894398
Entity Address, Address Line One	1180 Celebration Boulevard, Suite 103
Entity Address, City or Town	Celebration
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	34747
City Area Code	321
Local Phone Number	939-3416
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ZVRA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float				$ 152,900,000
Entity Common Stock, Shares Outstanding			34,540,414
Auditor Firm ID	42	49
Auditor Name	Ernst & Young LLP	RSM US LLP
Auditor Location	Orlando, Florida	Orlando, Florida

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents	$ 65,466	$ 112,346
Securities at fair value	16,900	0
Short-term investments - other	481	0
Accounts and other receivables	8,299	1,528
Prepaid expenses and other current assets	1,877	1,182
Total current assets	93,023	115,056
Inventories	671	0
Property and equipment, net	794	884
Operating lease right-of-use assets	988	1,141
Securities at fair value	0	14,932
Long-term investments - other	20,000	490
Other long-term assets	53	438
Total assets	115,529	132,941
Liabilities and stockholders’ equity (deficit)
Accounts payable and accrued expenses	6,169	3,038
Current portion of operating lease liabilities	480	356
Current portion of discount and rebate liabilities	4,655	0
Other current liabilities	422	836
Total current liabilities	11,726	4,230
Line of credit payable	12,800	0
Derivative and warrant liability	1	330
Operating lease liabilities, less current portion	843	1,232
Discount and rebate liabilities, less current portion	4,327	0
Other long-term liabilities	25	31
Total liabilities	29,722	5,823
Commitments and contingencies (Note H)
Stockholders' equity:
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2022 or December 31, 2021	0	0
Common stock, $0.0001 par value, 250,000,000 shares authorized, 35,450,257 shares issued and 34,540,304 shares outstanding as of December 31, 2022; 35,325,801 shares issued and 35,005,640 shares outstanding as of December 31, 2021	3	4
Additional paid-in capital	401,799	396,957
Treasury stock, at cost	(7,536)	(2,814)
Accumulated deficit	(308,572)	(267,029)
Accumulated other comprehensive income	113	0
Total stockholders' equity	85,807	127,118
Total liabilities and stockholders' equity	$ 115,529	$ 132,941

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	35,450,257	35,325,801
Common stock, shares outstanding (in shares)	34,540,304	35,005,640

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue, net	$ 10,458,000	$ 28,650,000
Operating expenses:
Cost of revenue	343,000	2,059,000
Research and development	19,614,000	10,161,000
General and administrative	15,343,000	8,701,000
Acquired in-process research and development	17,663,000	0
Total operating expenses	52,963,000	20,921,000
(Loss) income from operations	(42,505,000)	7,729,000
Other (expense) income:
Loss on extinguishment of debt	0	(16,096,000)
Interest expense related to amortization of debt issuance costs and discount	0	(150,000)
Interest expense	(335,000)	(226,000)
Fair value adjustment related to derivative and warrant liability	328,000	(26,000)
Fair value adjustment related to investments	(577,000)	(13,000)
Interest and other income, net	760,000	261,000
Total other income (expense)	176,000	(16,250,000)
Loss before income taxes	(42,329,000)	(8,521,000)
Income tax benefit (expense)	786,000	(34,000)
Net income (loss)	(41,543,000)	(8,555,000)
Deemed dividend	0	(54,342,000)
Net loss attributable to common stockholders	$ (41,543,000)	$ (62,897,000)
Basic and diluted net loss per share of common stock:
Net loss attributable to common stockholders (in dollars per share)	$ (1.20)	$ (2.11)
Weighted average number of shares of common stock outstanding:
Basic and diluted (in shares)	34,488,800	29,766,347

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss attributable to common stockholders	$ (41,543)	$ (62,897)
Other comprehensive income:
Foreign currency translation adjustment	113	0
Other comprehensive income	113	0
Comprehensive loss	$ (41,430)	$ (62,897)

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Underwritten Public Offering [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	Underwritten Public Offering [Member] Common Stock [Member]	Underwritten Public Offering [Member] Additional Paid-in Capital [Member]	Underwritten Public Offering [Member] Treasury Stock [Member]	Underwritten Public Offering [Member] Retained Earnings [Member]	Underwritten Public Offering [Member] AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]	January 2021 Inducement Warrants [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	January 2021 Inducement Warrants [Member] Common Stock [Member]	January 2021 Inducement Warrants [Member] Additional Paid-in Capital [Member]	January 2021 Inducement Warrants [Member] Treasury Stock [Member]	January 2021 Inducement Warrants [Member] Retained Earnings [Member]	January 2021 Inducement Warrants [Member] AOCI Attributable to Parent [Member]	January 2021 Inducement Warrants [Member]	Warrants to Purchase Common Stock [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	Warrants to Purchase Common Stock [Member] Common Stock [Member]	Warrants to Purchase Common Stock [Member] Additional Paid-in Capital [Member]	Warrants to Purchase Common Stock [Member] Treasury Stock [Member]	Warrants to Purchase Common Stock [Member] Retained Earnings [Member]	Warrants to Purchase Common Stock [Member] AOCI Attributable to Parent [Member]	Warrants to Purchase Common Stock [Member]	Exchange Warrants [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	Exchange Warrants [Member] Common Stock [Member]	Exchange Warrants [Member] Additional Paid-in Capital [Member]	Exchange Warrants [Member] Treasury Stock [Member]	Exchange Warrants [Member] Retained Earnings [Member]	Exchange Warrants [Member] AOCI Attributable to Parent [Member]	Exchange Warrants [Member]	June 2021 Inducement Warrants [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	June 2021 Inducement Warrants [Member] Common Stock [Member]	June 2021 Inducement Warrants [Member] Additional Paid-in Capital [Member]	June 2021 Inducement Warrants [Member] Treasury Stock [Member]	June 2021 Inducement Warrants [Member] Retained Earnings [Member]	June 2021 Inducement Warrants [Member] AOCI Attributable to Parent [Member]	June 2021 Inducement Warrants [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Common Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Additional Paid-in Capital [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Treasury Stock [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] Retained Earnings [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Facility Notes into Series B-2 Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Preferred Stock [Member] Undesignated Preferred Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Common Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Treasury Stock [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] Retained Earnings [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member] AOCI Attributable to Parent [Member]	Conversion of Series B-2 Preferred Stock into Common Stock [Member]	Preferred Stock [Member] Undesignated Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2020																																																		$ 0	$ 0	$ 192,062	$ 0	$ (258,474)		$ (66,412)
Net income (loss)																																																		0	0	0	0	(8,555)		(8,555)
Stock-based compensation expense																																																		0	0	2,436	0	0		2,436
Issuance of common stock in connection with Public Offering, net of discounts and commissions	$ 0	$ 1	$ 49,284	$ 0	$ 0		$ 49,285
Issuance of common stock in connection with the exercise of warrants in the January 2021 Inducement Transaction, net of discounts and commissions								$ 0	$ 1	$ 40,390	$ 0	$ 0		$ 40,391
Issuance of common stock in connection with the exercise of common stock warrants															$ 0	$ 0	$ 30,819	$ 0	$ 0		$ 30,819								$ 0	$ 1	$ 36,559	$ 0	$ 0		$ 36,560
Fair value of warrants issued								0	0	38,437	0	0		38,437								$ 0	$ 0	$ 15,990	$ 0	$ 0		$ 15,990	0	0	17,089	0	0		17,089
Issuance of stock as a result of conversion																																				$ 29,056	$ 0	$ 0	$ 0	$ 0		$ 29,056	$ (29,056)	$ 1	$ 29,055	$ 0	$ 0		$ 0
Deemed dividend related the Inducement Transaction								$ 0	$ 0	$ (37,444)	$ 0	$ 0		$ (37,444)															$ 0	$ 0	$ (16,898)	$ 0	$ 0		$ (16,898)
Shares repurchased as part of the Share Repurchase Program																																																		0	0	0	(2,814)	0		(2,814)
Offering expenses charged to equity																																																		0	0	(1,124)	0	0		(1,124)
Issuance of common stock in exchange for consulting services																																																		0	0	302	0	0		302
Balance at Dec. 31, 2021																																																		0	4	396,957	(2,814)	(267,029)	0	127,118
Other comprehensive income																																																								0
Net income (loss)																																																		0	0	0	0	(41,543)	0	(41,543)
Stock-based compensation expense																																																		0	0	4,294	0	0	0	4,294
Issuance of common stock in exchange for consulting services																																																			0	224	0	0	0	224
Balance at Dec. 31, 2022																																																		0	3	401,799	(7,536)	(308,572)	113	85,807
Shares repurchased as part of the Share Repurchase Program																																																		0	(1)	0	(4,722)	0	0	(4,723)
Issuance of common stock as part of the Employee Stock Purchase Plan																																																			0	324	0	0	0	324
Other comprehensive income																																																		$ 0	$ 0	$ 0	$ 0	$ 0	$ 113	$ 113

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (41,543)	$ (8,555)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on extinguishment of debt	0	16,096
Stock-based compensation expense	4,294	2,436
Non-cash interest expense	0	8
Amortization of debt issuance costs and debt discount	0	150
Depreciation and amortization expense	944	257
Fair value adjustment related to derivative and warrant liability	(328)	26
Fair value adjustment related to investments	577	0
Loss on sublease and disposal of property and equipment	9	76
Consulting fees paid in common stock	224	302
Acquired in-process research and development	17,663	0
Gain on foreign currency exchange rates	(91)	0
Change in assets and liabilities:
Accounts and other receivables	(6,772)	1,051
Prepaid expenses and other assets	(657)	(825)
Inventories	147	0
Operating lease right-of-use assets	277	133
Other long-term assets	386	0
Accounts payable and accrued expenses	3,131	(1,113)
Discount and rebate liabilities	3,782	0
Operating lease liabilities	(389)	(326)
Other liabilities	(371)	723
Net cash (used in) provided by operating activities	(18,717)	10,439
Cash flows from investing activities:
Acquisitions, net	(14,090)	0
Purchases of property and equipment	(93)	(102)
Purchases of long-term investments, net	(22,536)	(15,422)
Net cash used in investing activities	(36,719)	(15,524)
Cash flows from financing activities:
Proceeds from Public Offering, net of discounts and commissions	0	49,285
Proceeds from Inducement Transaction, net of discounts and commissions	0	36,751
Proceeds from issuance of debt	12,800	0
Proceeds from insurance financing arrangements	1,273	0
Proceeds from Employee Stock Purchase Plan	324	0
Payments of principal on insurance financing arrangements	(1,306)	0
Payment to repurchase shares as part of the Share Repurchase Program	(4,723)
Payment of offering costs	0	(1,338)
Repayment of principal on finance lease liabilities	(16)	(173)
Payment of debt issuance costs	0	(2,881)
Repayment of principal on convertible notes	0	(37,924)
Net proceeds from exercise of common stock warrants	0	30,819
Net cash provided by financing activities	8,352	113,109
Effect of exchange rate changes on cash and cash equivalents	204	0
Net (decrease) increase in cash and cash equivalents	(46,880)	108,024
Cash and cash equivalents, beginning of period	112,346	4,322
Cash and cash equivalents, end of period	65,466	112,346
Supplemental cash flow information:
Cash paid for interest	321	218
Right-of-use assets obtained in exchange for lease liabilities	123	0
Amounts due for deferred offering costs included in accounts payable and accrued expenses	0	48
Fair value of warrants issued to underwriters in connection with Public Offering	0	3,485
Conversion of Facility Notes into Series B-2 Preferred Stock [Member]
Supplemental cash flow information:
Facility Notes principal converted to Series B-2 Preferred Stock	0	31,477
Warrants Issued in Connection with January 2021 Inducement Transaction [Member]
Cash flows from financing activities:
Proceeds from Inducement Transaction, net of discounts and commissions	$ 0	$ 41,384

Note A - Description of Busines

Note A - Description of Business, Basis of Presentation, and Significant Transactions	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	A. Description of Business, Basis of Presentation, and Significant Transactions Organization Zevra Therapeutics, Inc . (t first KP1077, KP415, six February 21, 2023. Basis of Presentation The Company prepared the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the Company’s opinion, reflect all adjustments, including normal recurring items that are necessary. All significant intercompany accounts and transactions have been eliminated in consolidation. Arimoclomol Acquisition On May 15, 2022, Zevra Denmark A/S (formerly known as KemPharm Denmark A/S prior to February 21, 2023) ( May 31, 2022. The Company accounted for the arimoclomol acquisition as an asset acquisition as the majority of the value of the assets acquired related to the arimoclomol acquired in-process research and development (“IPR&D”) asset. The intangible asset associated with IPR&D relates to arimoclomol. The estimated fair value of $17.7 million was determined using the excess earnings valuation method, a variation of the income valuation approach. The excess earnings valuation method estimates the value of an intangible asset equal to the present value of the incremental after-tax cash flows attributable to that intangible asset over its remaining economic life. Some of the more significant assumptions utilized in our asset valuations included projected revenues, probability of commercial success, and the discount rate. The fair value using the excess earnings valuation method was determined using an estimated weighted average cost of capital of 42%, which reflects the risks inherent in future cash flow projections and represents a rate of return that a market participant would expect for this asset. This fair value measurement was based on significant inputs not 3 In accordance with Accounting Standards Codification (ASC) Subtopic 730 10 25, Accounting for Research and Development Costs not no December 31, 2022, The following represents the consideration paid and purchase price allocation for the acquisition of arimoclomol (in thousands): Cash $ 12,800 Assumed reserve liability 5,200 Total consideration $ 18,000 Total consideration 18,000 Direct transaction costs associated with the acquisition (1) 1,290 Total purchase price to be allocated $ 19,290 Property and equipment, inventory and assembled workforce acquired 1,627 IPR&D (2) 17,663 Total allocated purchase price $ 19,290 ( 1 ( 2 Underwriting Agreement On January 8, 2021, 1 No. 333 250945 On January 8, 2021, February 1, 2021, On January 12, 2021, On January 25, 2022, 1 No. 333 250945 3 February 1, 2022. Listing on the Nasdaq Stock Market On January 7, 2021, January 8, 2021, On October 19, 2021, October 19, 2021, January 2021. On March 1, 2023, Entry into 2021 ATM Agreement On July 2, 2021, “2021 may 2021 3. may 415 1933, may 2021 3 2021 July 12, 2021. December 31, 2022 2021, 2021 Share Repurchase Program On December 20, 2021, may December 31, 2023. may 10b 18 1934, not may December 31, 2022, Reclassifications Certain reclassifications were made to the 2021 2022. no

Note B - Summary of Significant

Note B - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	B. Summary of Significant Accounting Policies Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of long-term investments, the fair value of the derivative and warrant liability and discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit and investments with multiple financial institutions, the balances of which frequently exceed insured limits, and accounts receivable, which are concentrated amongst a limited number of customers. Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three Investments The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under ASC 825, Financial Instruments. As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the consolidated statements of operations. The securities primarily consist of U.S. Treasury securities and U.S. government-sponsored agency securities and are included in Securities at fair value in the consolidated balance sheets. As of December 31, 2022, 2021, s. In addition, the Company holds certificates of deposit totaling $20.5 million and $0.5 million as of December 31, 2022, 2021, Property and Equipment The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three ten Debt Issuance Costs Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. In the first 2021, 2 Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying values, an impairment loss is recorded for the difference between the carrying values and fair values of the asset. No such impairment occurred for the years ended December 31, 2022 2021 . Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers 606” five 1 2 3 4 5 Arimoclomol Early Access Program Net revenue includes revenue from the sale of arimoclomol for the treatment of NPC under the remunerated early access compassionate use program in France (“French nATU”). An early access compassionate use program is a program giving specific patients access to a drug, which is not no 606, December 31, 2022, December 31, 2022, December 31, 2022, December 31, 2022, Licensing Agreements The Company enters into licensing agreements with licensees that fall under the scope of ASC 606. The terms of the Company’s licensing agreements typically include one may As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may Up-front Fees Milestone Payments not not not may AZSTARYS License Agreement In September 2019, In April 2021, No. 1 March 2, 2021. May 7, 2021. Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the AZSTARYS License Agreement. As part of this agreement, the Company is obligated to perform consulting services on behalf of Commave related to the licensed products. For these consulting services, Commave has agreed to pay the Company a set rate per hour on any consulting services performed on behalf of Commave for the benefit of the licensed products. In accordance with the terms of the Company’s March 20, 2012 KP879 KP1077 The AZSTARYS License Agreement is within the scope of ASC 606, not 606, third two $10.0 The consideration allocated to the grant of the exclusive, worldwide license was $10.0 The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and the achievement of certain U.S. sales milestones. Further, Commave will pay the Company quarterly, tiered royalty payments based on a range of percentages of Net Sales (as defined in the AZSTARYS License Agreement). The Company concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and are not not not December 31, 2022, 2021, million and $20.9 million, respectively. There was no deferred revenue related to this agreement as of December 31, 2022, 2021. Consulting Arrangements The Company enters into consulting arrangements with third 606. may third Corium Consulting Agreement In July 2020, Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which was paid in quarterly installments through March 31, 2022. first 2022. 606, not third third not not not The Company determined that the performance of consulting services, including reimbursement of third third 606 December 31, 2022, third For the years ended December 31, 2022, 2021, December 31, 2022, December 31, 2021, Other Consulting Arrangements For the years ended December 31, 2022, 2021, f $0.1 million and $0.1 million, respectively. There was no deferred revenue from other consulting arrangements as of December 31, 2022, 2021. Accounts and Other Receivables Accounts and other receivables consist of receivables under the AZSTARYS License Agreement and Arimoclomol EAP, as well as receivables related to consulting arrangements, income tax receivables and other receivables due to the Company. Receivables under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable third Inventory As discussed in Note A, a portion of the purchase price was allocated to inventory acquired representing the value of inventory associated with forecasted EAP revenues and as of December 31, 2022, first first The Company may may not may not December 31, 2022, 2021, not Research and Development Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clin ical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services. The Company enters into contractual agreements with third pleted over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations. Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not Uncertain tax positions are recognized only when the Company believes it is more likely than not t the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not December 31, 2022 2021 The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no 2015, 2017 may On December 22, 2017, 1, 2018 ” ("Ta x January 1, 2018, not Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers an d directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505 50 . The Company values equity instruments and stock options granted using the Black-Scholes option pricing model. Basic and Diluted Net Loss per Share of Common Stock The Company uses the two entitle the holders to participate in dividends and earnings of the Company. The two Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is ava ilable and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. The Company holds assets in both the United States and Europe as of December 31, 2022 2021 Foreign currency Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying consolidated statements of stockholders’ equity. Application of New or Revised Accounting Standards — Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In August 2020, No. 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06” December 15, 2021, 2020 06 not In May 2021, No. 2021 04, Earnings Per Share (Topic 260 Modifications and Extinguishments (Subtopic 470 50 Stock Compensation (Topic 718 Contracts in Entity s Own Equity (Subtopic 815 40 s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the FASB Emerging Issues Task Force 2021 04” December 15, 2021, 2021 04 not

Note C - Accounts and Other Rec

Note C - Accounts and Other Receivables	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	C. Accounts and Other Receivables Accounts and other receivables consist of the following (in thousands): December 31, 2022 2021 Accounts receivable $ 7,185 $ 1,421 Other receivables 1,114 107 Total accounts and other receivables $ 8,299 $ 1,528

Note D - Prepaid Expenses and O

Note D - Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Other Current Assets [Text Block]	D. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): December 31, 2022 2021 Prepaid insurance $ 577 $ 637 Prepaid offering costs - 293 Other prepaid expenses and current assets 1,300 252 Total prepaid expenses and other current assets $ 1,877 $ 1,182

Note E - Property and Equipment

Note E - Property and Equipment	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	E. Property and Equipment Property and equipment consists of the following (in thousands): December 31, 2022 2021 Laboratory equipment $ 710 $ 645 Furniture and office equipment 104 71 Computers and hardware 462 338 Leasehold improvements 710 724 Finance lease right-of-use assets 251 1,031 Total property and equipment 2,237 2,809 Less: accumulated depreciation and amortization (1,443 ) (1,925 ) Property and equipment, net $ 794 $ 884 The estimated useful lives of property and equipment are as follows: Useful Life Asset Category (in years) Laboratory equipment 10 Furniture and office equipment 5 - 10 Computers and hardware 3 - 7 Leasehold improvements 9 Depreciation and amortization expense, including amounts pertaining to assets held under finance leases, was approximately $298,000 and $257,000 for the years ended December 31, 2022 2021

Note F - Accounts Payable and A

Note F - Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	F. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following (in thousands): December 31, 2022 2021 Accrued banking fees - 700 Accrued payroll 1,673 1,054 Accrued professional fees 256 259 Accounts payable 3,611 516 Other accrued expenses 629 509 Total accounts payable and accrued expenses $ 6,169 $ 3,038

Note G - Debt Obligations

Note G - Debt Obligations	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	G. Debt Obligations Deerfield Facility Agreement In June 2014, first Pursuant to the Deerfield Facility Agreement, the Company issued to Deerfield a warrant to purchase 14,423,076 shares of Series D Preferred, which is exercisable until June 2, 2024, December 2022 260, Earnings per Share may The Company recorded the fair value of the shares of Series D Preferred to debt issuance costs on the date of issuance. The Company also recorded the fair value of the OTA Warrant and the embedded Warrant Put Option to debt discount on the date of issuance. The debt issuance costs and debt discount were amortized over the term of the related debt and the expense was recorded as interest expense related to amortization of debt issuance costs and discount in the consolidated statements of operations. As discussed below, in the first 2021, 2 5.50% Senior Convertible Notes In February 2016, 2021 “2021 2021 144A 1933, As described in more detail below, in multiple exchanges, all outstanding 2021 2021 Note Exchange Effected in December 2019 In December 2019, December 2019 “December 2019 “December 2019 December 2019 “December 2019 2021 December 2019 2021 Note Exchange Effected in January 2020 In January 2020, January 2020 “January 2020 January 2020 “January 2020 2021 December 2020 Exchange Agreement and Amendment to Facility Agreement, Notes and Investors Rights Agreement In December 2020, December 2020 “December 2020 December 2020 December 2019 January 2020 2 “December 2020 In anticipation of the Public Offering, and to meet the Nasdaq Listing Requirements, the Company agreed in December 2020 December 2019 January 2020 Under the terms of the December 2020 January 12, 2021, ● Exchanged $31.5 million of the outstanding principal and accrued interest on the Facility Notes for (i) 31,476.98412 shares of Series B- 2 ● Made the Debt Payment, in partial repayment of the remaining outstanding principal and accrued interest of the Facility Notes. Following the completion of these transactions, the aggregate balance of principal and accrued interest remaining outstanding under the Facility Notes was approximately $7.6 million. With respect to this remaining outstanding balance under the Facility Notes, the December 2020 ● The maturity date was amended to March 31, 2023, ● Interest would accrue at the rate of 6.75% per annum, payable quarterly, would be added to principal until June 30, 2021, The changes to the Facility Notes, under the December 2020 December 2020 December 2020 not December 31, 2021, Payoff of Facility Agreement Notes and Termination of Facility Agreement On February 8, 2021, Pursuant to the payoff letter, the Company paid a total of $8.0 million to the Facility Agreement Note Holders, representing the principal balance, accrued interest outstanding and a prepayment fee in repayment of the Company’s outstanding obligations under the Facility Agreement. Pursuant to the payoff letter, all outstanding indebtedness and obligations of the Company owing to the Facility Agreement Note Holders under the Facility Agreement have been paid in full. The Facility Agreement and the notes thereunder, as well as the security interests in the assets of the Company securing the Facility Agreement and note obligations, have been terminated. The Facility Agreement Note Holders will retain the warrants previously issued to them by the Company. The Company determined the payoff letter met the liability derecognition threshold under ASC 405 20, Liabilities - Extinguishment of Liabilities no December 31, 2021. PPP Loan On April 23, 2020, may May 2021, December 31, 2021. Line of Credit On May 31, 2022, The revolving facility under the Line of Credit is secured by a perfected security interest in deposit accounts. The revolving facility under the Line of Credit is subject to customary affirmative and negative covenants. The latest maturity date of the loans under the Line of Credit is May 31, 2025. December 31, 2022, December 31, 2022. On January 26, 2023, On January 31, 2023,

Note H - Commitments and Contin

Note H - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	H. Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not not December 31, 2022, 2021,

Note I - Preferred Stock and Wa

Note I - Preferred Stock and Warrants	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Preferred Stock [Text Block]	I. Preferred Stock and Warrants Authorized, Issued, and Outstanding Preferred Stock As of December 31, 2022, 2021, As of December 31, 2022, 2021, Series B- 2 Preferred Stock Pursuant to the December 2020 January 12, 2021, 2 2 Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of the Series B- 2 Convertible Preferred Stock On January 11, 2021, December 2020 2 2 2 Immediately following the closing of the Public Offering, pursuant to the terms of the December 2020 ● exchanged approximately $31.5 million of the outstanding principal and accrued interest on the Facility Notes for (i) the Series B- 2 ● made a payment of approximately $30.3 million in partial repayment of the remaining outstanding principal and accrued interest on the Facility Notes. In March 2021, 2

Note J - Common Stock and Warra

Note J - Common Stock and Warrants	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	J. Common Stock and Warrants Authorized, Issued, and Outstanding Common Shares As of December 31, 2022, 2021, December 31, 2022, 2021, December 31, 2022, 2021, As of December 31, 2022, 2021, December 31, 2022 2021 Outstanding awards under equity incentive plans 2,456,407 1,273,879 Outstanding common stock warrants 4,252,600 4,252,600 Possible future issuances under equity incentive plans 4,421,508 4,209,935 Possible future issuances under employee stock purchase plan 1,417,365 1,500,000 Total common shares reserved for future issuance 12,547,880 11,236,414 Common Stock Activity The following table summarizes common stock activity for the years ended December 31, 2022 2021 Shares of Common Stock Balance as of January 1, 2021 4,537,321 Common stock issued as a result of the Public Offering 7,139,498 Common stock issued as a result of Series B-2 Preferred Stock conversions 4,842,699 Common stock issued as a result of warrant exercises 18,772,510 Common stock issued as compensation to third-parties 35,129 Adjustment for cash paid in lieu of DTC fractional shares (1,356 ) Common stock repurchased as a result of the Stock Repurchase Program (320,161 ) Balance as of December 31, 2021 35,005,640 Common stock issued as compensation to third-parties 41,821 Common stock repurchased as a result of the Stock Repurchase Program (589,792 ) Common stock issued as a result of the Employee Stock Purchase Plan 82,635 Balance as of December 31, 2022 34,540,304 Warrants On June 2, 2014, June 2, 2024, December 2020, January 2021 $93.60 June 2021 $46.25 February 2021 The Company determined that the OTA Warrant should be recorded as a liability and stated at fair value at each reporting period upon inception. As stated above, upon completion of the IPO, the OTA Warrant automatically converted into warrants to purchase the Company’s common stock. The OTA Warrant remains classified as a liability and is recorded at fair value at each reporting period since it can be settled in cash. Changes to the fair value of the warrant liability are recorded through the consolidated statements of operations as a fair value adjustment (Note L). In connection with the APADAZ License Agreement, in October 2018, not four October 24, 2023. may December 2020, The Company determined that, since KVK qualifies as a customer under ASC 606, 815 815 606 Pre-Funded Warrants On January 12, 2021, January 2021, Warrants to Purchase Common Stock On January 12, 2021, December 2020 December 2020 fifth may not not not December 31, 2022, January 2021 Underwriter Warrant On January 12, 2021, February 3, 2021, December 31, 2022, January 2021 Warrant Exercise Inducement Letters and Issuance of Warrants On January 26, 2021, “January 2021 “January 2021 January 2021 January 2021 The January 2021 fifth January 2021 January 2021 may may not January 2021 January 2021 January 2021 January 2021 not January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 January 2021 not January 2021 January 2021 January 2021 December 31, 2022, January 2021 January 2021 June 2021 In accordance with the January 2021 December 31, 2021, January 2021 January 2021 June 2021 Warrant Exercise Inducement Letters and Issuance of Warrants On June 18, 2021, “June 2021 January 2021 "January 2021 “June 2021 January 2021 “June 2021 January 2021 January 2021 June 2021 June 2021 January 2021 June 2021 June 2021 The June 2021 December 31, 2026. June 2021 June 2021 may may not June 2021 June 2021 June 2021 June 2021 not June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 June 2021 not June 2021 June 2021 June 2021 December 31, 2022, 2021, June 2021 In accordance with the June 2021 December 31, 2021, June 2021 June 2021

Note K - Stock-based Compensati

Note K - Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	K. Stock-Based Compensation The Company maintains a stock-based compensation plan (the “Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO. In November 2014, April 2015, 2014 “2014 April 2015. 2014 June 2021, 2014 2014 April 2021, January 1, 2031 2014 162 may 2014 December 31, 2022. 2014 January 1 January 1, 2016, January 1, 2031, December 31 2014 January 1, 2023, 2014 During the years ended December 31, 2022, 2021, In June 2021, April 2021. may first October 1, 2021, first May 31, 2022. December 31, 2022, In January 2023, 2023 “2023 may 2023 Stock-based compensation expense recorded under the Incentive Stock Plan, 2014 2014 Year ended December 31, 2022 2021 Research and development $ 1,443 $ 914 General and administrative 2,851 1,522 Total stock-based compensation expense $ 4,294 $ 2,436 Stock Option Awards The Company estimates the fair value of stock options using the Black-Scholes option-pricing model, which requires the use of subjective assumptions, including the expected term of the option, the expected stock price volatility, expected dividend yield and the risk-free interest rate for the expected term of the option. The expected term represents the period of time the stock options are expected to be outstanding. Due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected term of the stock options, the Company uses the simplified method to estimate the expected term for its “plain vanilla” stock options. Under the simplified method, the expected term of an option is presumed to be the mid-point between the vesting date and the end of the contractual term. Some options, for example those that have exercise prices in excess of the fair value of the underlying stock, are not not not The Company recognizes compensation expense related to stock-based payment transactions upon satisfaction of the requisite service or vesting requirements. Forfeitures are estimated at the time of grant and revised based on actual forfeitures, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Using the Black-Scholes option-pricing model, the weighted-average fair value of awards granted during the years ended December 31, 22 2021, Year Ended December 31, 2022 2021 Risk-free interest rate 1.70% - 3.80% 0.92% - 1.55% Expected term (in years) 5.50 - 7.00 5.50 - 10.00 Expected volatility 91.28% - 98.91% 96.91% - 102.57% Expected dividend yield 0 0 The activity under the Incentive Stock Plan, 2014 2014 for the year ended December 31, 2022 , Weighted Weighted Avg Aggregate Number of Average Remaining Intrinsic Options Exercise Price Contractual Term Value Outstanding balance at January 1, 2022 1,273,879 $ 27.58 8.73 $ 254,207 Granted 1,434,245 $ 6.32 Exercised or released - $ - Canceled or forfeited 245,593 $ 9.23 $ 74,033 Expired 6,124 $ 93.60 Outstanding balance at December 31, 2022 2,456,407 $ 16.84 8.51 $ 11,819 Exercisable at December 31, 2022 615,001 $ 44.52 6.99 $ 2,722 Vested and expected to vest at December 31, 2022 2,375,700 $ 17.15 8.49 $ 11,628 Information regarding currently outstanding and exercisable options as of December 31, 2022 , Options Outstanding Options Exercisable Weighted Avg Weighted Avg Number of Remaining Number of Remaining Exercise Price Shares Contractual Term Shares Contractual Term $2.848 to $10.00 2,175,436 8.90 351,151 8.19 $10.01 to $30.00 69,375 8.17 69,375 8.17 $30.01 to $50.00 68,514 6.11 51,393 6.11 $50.01 to $70.00 41,866 4.08 41,866 4.08 $70.01 to $327.20 101,216 3.70 101,216 3.70 2,456,407 8.51 615,001 6.99 The total fair value of stock options vested during the years ended December 31, 2022 2021 Unvested stock options as of December 31, 2022 2021 Number of Unvested Options December 31, Exercise Price 2022 2021 $2.848 to $10.00 1,824,285 861,139 $10.01 to $30.00 - 60,000 $30.01 to $50.00 17,121 36,190 $50.01 to $70.00 - - $70.01 to $327.20 - 9,335 Total number of unvested stock options 1,841,406 966,664 As of December 31, 2022 , 2014 2014 There was $0.4 million and $0.4 million stock-based compensation expense related to performance-based awards recognized during the years ended December 31, 2022, 2021,

Note L - Fair Value of Financia

Note L - Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	L. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three three ● Level 1—Observable ● Level 2—Observable ● Level 3—Unobservable no The carrying amounts of certain financial instruments, including cash and cash equivalents and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2022 2021 Quoted Prices Significant in Active Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) OTA Warrant liability $ 1 $ - $ - $ 1 Total liabilities $ 1 $ - $ - $ 1 Securities: U.S. government-sponsored agency securities $ 7,189 $ - $ 7,189 $ - U.S. Treasury securities 9,711 9,711 - - Total assets $ 16,900 $ 9,711 $ 7,189 $ - Quoted Prices Significant in Active Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2021 (Level 1) (Level 2) (Level 3) OTA Warrant liability $ 288 $ - $ - $ 288 Embedded Warrant Put Option 18 - - 18 KVK Warrant liability 24 - 24 - Total liabilities $ 330 $ - $ 24 $ 306 The Company’s OTA Warrant liability, embedded Warrant Put Option and securities are measured at fair value on a recurring basis. As of December 31, 2022, 2021, December 31, 2022, 2021, December 31, 2022, 2021, The derivative liability for the OTA Warrant was $1,000 and $288,000 at December 31, 2022, 2021, December 31, 2022, 2021, 10% fourth 2023. The Company’s KVK Warrant liability is measured at fair value on a recurring basis. As of December 31, 2022, 2021, no not not December 31, 2022, 2021, A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 2022 2021 Balance as of beginning of period $ 306 $ 255 Adjustment to fair value (305 ) 51 Balance as of end of period $ 1 $ 306

Note M - Income Taxes

Note M - Income Taxes	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	M. Income Taxes The Company ’s financial statements include a total state tax expense of $31,000 and state tax benefit of $34,000 related to research and development credits on a loss before income taxes of approximately $42.3 million and $8.5 million for the years ended December 31, 2022 2021 31, 2022. Year ended December 31, 2022 2021 Federal statutory rate 21.00 % 21.00 % Effect of: Change in valuation allowance (22.06 ) (28.39 ) Return to provision and deferred true-up (3.41 ) (0.26 ) Federal research and development credit 1.16 - State research and development credit 0.07 - Change in rate 0.51 3.00 State tax benefit (net of federal) 3.03 5.14 Warrant liability 0.16 (0.06 ) Stock-based compensation (0.69 ) (2.68 ) PPP Loan forgiveness - 1.94 Global intangible low-taxed income credit (1.22 ) - Foreign research and development excess benefit 3.16 - Other 0.15 (0.08 ) Federal income tax provision effective rate 1.86 % (0.39 )% The components of deferred tax assets and liabilities are as follows (in thousands): December 31, 2022 2021 Deferred tax assets relating to: Net operating loss carryforwards $ 66,373 $ 60,977 Research and development tax carryforward 6,900 6,411 Stock-based compensation 4,185 4,807 174 expenses 3,730 - Right-of-use liability 359 424 Property and equipment 22 14 Other deferred tax assets 598 288 Total gross deferred tax assets 82,167 72,921 Deferred tax liabilities relating to: Right-of-use asset (336 ) (401 ) Other deferred tax liabilities - (9 ) Total gross deferred tax liabilities (336 ) (410 ) Deferred tax assets less liabilities 81,831 72,511 Valuation allowance (81,831 ) (72,511 ) Net deferred tax asset (liability) $ - $ - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not not assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based upon the level of historical taxable income (losses) and projections for future taxable income (losses) over the periods in which the deferred tax assets are deductible, management believes it is more likely than not not The Company recorded certain retainable research and development tax credits as income tax benefit in the consolidated statement of operations for the year ended December 31, 2022. no In accordance with the Tax Cuts and Jobs Act of 2017, not no The Company has federal operating loss carryforwards totaling $236.0 not no The Company also has certain state net operating loss carryforwards totaling $225.2 million, which, if not may 382 may imitations on the Company’s ability to utilize the net operating loss carryforward. ASC 740 10, Accounting for Uncertainty in Income Taxes not” not not not not On March 27, 2020, 19 no

Note N - Net Loss Per Share

Note N - Net Loss Per Share	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	N. Net Loss Per Share For all periods presented herein, the Company did not two not two Under the two No no two two two As noted above, for all periods presented herein, the Company did not two no The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive: December 31, 2022 2021 Awards under equity incentive plans 2,456,407 1,273,879 Common stock warrants 4,252,600 4,221,350 Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 6,709,007 5,495,229 A reconciliation from net loss to basic net loss attributable to common stockholders per share of common stock and diluted net loss attributable to common stockholders per share of common stock for the years ended December 31, 2022, 2021, December 31, 2022 2021 Basic and diluted net loss per share of common stock: Net loss $ (41,543 ) $ (8,555 ) Less: Dividends declared or accumulated - (54,342 ) Net loss attributable to common stockholders $ (41,543 ) $ (62,897 ) Less: Net loss attributable to participating securities $ - $ - Undistributed net loss attributable to shares of common stockholders, basic and diluted $ (41,543 ) $ (62,897 ) Weighted average number of shares of common stock outstanding, basic and diluted 34,489 29,766 Basic and diluted net loss attributable to common stockholders per share of common stock $ (1.20 ) $ (2.11 )

Note O - Leases

Note O - Leases	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Lease Disclosure [Text Block]	O. Leases The Company has operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. The Company determines if an arrangement is a lease at contract inception. Lease assets and lease liabilities are recognized based on the present value of lease payments over the lease term at the commencement date. The Company does not 12 not Effective June 1, 2021, one two February 2026. The components of lease expense were as follows (in thousands): Year Ended December 31, Lease Cost 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 129 $ 129 Interest on lease liabilities 2 9 Total finance lease cost 131 138 Operating lease cost 418 365 Short-term lease cost 210 199 Variable lease cost 39 47 Less: sublease income (157 ) (91 ) Total lease costs $ 641 $ 658 Supplemental cash flow information related to leases was as follows (in thousands): Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 2 $ 9 Financing cash flows from finance leases 16 173 Operating cash flows from operating leases 522 460 Operating cash flows from short-term leases 210 199 Operating cash flows from variable lease costs 39 47 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ - $ - Operating leases 123 - Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate): December 31, 2022 2021 Finance Leases Property and equipment, at cost $ 1,031 $ 1,031 less: accumulated depreciation and amortization (780 ) (651 ) Property and equipment, net $ 251 $ 380 Other current liabilities $ 6 $ 15 Other long-term liabilities - 6 Total finance lease liabilities $ 6 $ 21 Operating Leases Operating lease right-of-use assets $ 988 $ 1,141 Total operating lease right-of-use assets $ 988 $ 1,141 Current portion of operating lease liabilities $ 480 $ 356 Operating lease liabilities, less current portion 843 1,232 Total operating lease liabilities $ 1,323 $ 1,588 Weighted Average Remaining Lease Term Finance leases 1 year 1 year Operating leases 3 years 4 years Weighted Average Discount Rate Finance leases 14.3 % 12.0 % Operating leases 7.3 % 7.5 % Maturities on lease liabilities were as follows (in thousands): Finance Operating Year Ending December 31, Leases Leases 2023 $ 7 $ 563 2024 - 488 2025 - 389 2026 - 30 2027 - - Thereafter - - Total lease payments 7 1,470 Less: future interest expense (1 ) (147 ) Lease liabilities $ 6 $ 1,323

Note P - Employee Benefit Plan

Note P - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	P. Employee Benefit Plan The Company has a 401 “401 may 401 December 31, 2022, 2021, The Company has a discretionary profit sharing plan (the “Profit Sharing Plan”) that covers all employees. Employees become eligible participants in the Profit Sharing Plan once they have provided three 2022, 2021.

Note Q - Significant Events

Note Q - Significant Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Events [Text Block]	Q. Significant Events On January 6, 2023, January 6, 2023, 2023 In connection with Mr. Pascoe’s appointment as the Company’s Chief Executive Officer, the Company and Mr. Pascoe entered into an amendment to the employment agreement, dated November 5, 2021, 2014 January 9, 2023. first January 6, 2024 ( In connection with the management transition, the Company entered into (i) a transition agreement with Dr. Mickle (the “Transition Agreement”) and (ii) a consulting agreement with Dr. Mickle (the “Consulting Agreement”). Pursuant to the terms of the Transition Agreement, subject to his timely delivering a release of claims in the Company’s favor, Dr. Mickle will receive severance payments and benefits consisting of (i) continued payment of his base salary for 18 months following the date on which Dr. Mickle’s employment with the Company ends (the “Separation Date”), (ii) up to 18 months of continued medical, dental and vision coverage pursuant to COBRA and (iii) a one may 18 first 2023 2014

Note R - Subsequent Events

Note R - Subsequent Events	12 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	R. Subsequent Events The Company evaluated events and transactions occurring subsequent to December 31, 2022, rough March 7, 2023, no 2023

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, the useful lives of property and equipment, the recoverability of long-lived assets, the incremental borrowing rate for leases, and assumptions used for purposes of determining stock-based compensation, income taxes, the fair value of long-term investments, the fair value of the derivative and warrant liability and discount and rebate liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit and investments with multiple financial institutions, the balances of which frequently exceed insured limits, and accounts receivable, which are concentrated amongst a limited number of customers.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers any highly liquid investments with an original maturity of three
Investment, Policy [Policy Text Block]	Investments The Company maintains investment securities that are classified as available-for-sale securities for which the Company has elected the fair value option under ASC 825, Financial Instruments. As such, these securities are carried at fair value with unrealized gains and losses included in fair value adjustment related to investments on the consolidated statements of operations. The securities primarily consist of U.S. Treasury securities and U.S. government-sponsored agency securities and are included in Securities at fair value in the consolidated balance sheets. As of December 31, 2022, 2021, s. In addition, the Company holds certificates of deposit totaling $20.5 million and $0.5 million as of December 31, 2022, 2021,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three ten
Debt, Policy [Policy Text Block]	Debt Issuance Costs Debt issuance costs incurred in connection with financing arrangements are recorded as a reduction of the related debt on the balance sheet and amortized over the life of the respective financing arrangement using the effective interest method. In the first 2021, 2
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying values, an impairment loss is recorded for the difference between the carrying values and fair values of the asset. No such impairment occurred for the years ended December 31, 2022 2021 .
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers 606” five 1 2 3 4 5 Arimoclomol Early Access Program Net revenue includes revenue from the sale of arimoclomol for the treatment of NPC under the remunerated early access compassionate use program in France (“French nATU”). An early access compassionate use program is a program giving specific patients access to a drug, which is not no 606, December 31, 2022, December 31, 2022, December 31, 2022, December 31, 2022, Licensing Agreements The Company enters into licensing agreements with licensees that fall under the scope of ASC 606. The terms of the Company’s licensing agreements typically include one may As part of the accounting for these agreements, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligations. Generally, the estimation of the stand-alone selling price may Up-front Fees Milestone Payments not not not may AZSTARYS License Agreement In September 2019, In April 2021, No. 1 March 2, 2021. May 7, 2021. Commave also agreed to be responsible for and reimburse the Company for all of the development, commercialization and regulatory expenses incurred on the licensed products, subject to certain limitations as set forth in the AZSTARYS License Agreement. As part of this agreement, the Company is obligated to perform consulting services on behalf of Commave related to the licensed products. For these consulting services, Commave has agreed to pay the Company a set rate per hour on any consulting services performed on behalf of Commave for the benefit of the licensed products. In accordance with the terms of the Company’s March 20, 2012 KP879 KP1077 The AZSTARYS License Agreement is within the scope of ASC 606, not 606, third two $10.0 The consideration allocated to the grant of the exclusive, worldwide license was $10.0 The Company is entitled to additional payments from Commave conditioned upon the achievement of specified regulatory milestones related to AZSTARYS and the achievement of certain U.S. sales milestones. Further, Commave will pay the Company quarterly, tiered royalty payments based on a range of percentages of Net Sales (as defined in the AZSTARYS License Agreement). The Company concluded that these regulatory milestones, sales milestones and royalty payments each contain a significant uncertainty associated with a future event. As such, these milestone and royalty payments are constrained at contract inception and are not not not December 31, 2022, 2021, million and $20.9 million, respectively. There was no deferred revenue related to this agreement as of December 31, 2022, 2021. Consulting Arrangements The Company enters into consulting arrangements with third 606. may third Corium Consulting Agreement In July 2020, Under the Corium Consulting Agreement, the Company is entitled to receive payments from Corium of up to $15.6 million, $13.6 million of which was paid in quarterly installments through March 31, 2022. first 2022. 606, not third third not not not The Company determined that the performance of consulting services, including reimbursement of third third 606 December 31, 2022, third For the years ended December 31, 2022, 2021, December 31, 2022, December 31, 2021, Other Consulting Arrangements For the years ended December 31, 2022, 2021, f $0.1 million and $0.1 million, respectively. There was no deferred revenue from other consulting arrangements as of December 31, 2022, 2021.
Receivable [Policy Text Block]	Accounts and Other Receivables Accounts and other receivables consist of receivables under the AZSTARYS License Agreement and Arimoclomol EAP, as well as receivables related to consulting arrangements, income tax receivables and other receivables due to the Company. Receivables under the AZSTARYS License Agreement are recorded for amounts due to the Company related to reimbursable third
Inventory, Policy [Policy Text Block]	Inventory As discussed in Note A, a portion of the purchase price was allocated to inventory acquired representing the value of inventory associated with forecasted EAP revenues and as of December 31, 2022, first first The Company may may not may not December 31, 2022, 2021, not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Major components of research and development costs include cash compensation, stock-based compensation, depreciation and amortization expense on research and development property and equipment, costs of preclinical studies, clin ical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Costs incurred in research and development are expensed as incurred. The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the statements of operations as the Company receives the related goods or services. The Company enters into contractual agreements with third pleted over an extended period of time. The Company records liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with the applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when the Company has not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative expenses on the statements of operations.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using the tax rates that are expected to apply to taxable income for the years in which those tax assets and liabilities are expected to be realized or settled. Valuation allowances are recorded to reduce deferred tax assets to the amount the Company believes is more likely than not Uncertain tax positions are recognized only when the Company believes it is more likely than not t the tax position will be upheld on examination by the taxing authorities based on the merits of the position. The Company recognizes interest and penalties, if any, related to unrecognized income tax uncertainties in income tax expense. The Company did not December 31, 2022 2021 The Company files income tax returns in the United States for federal and various state jurisdictions. With few exceptions, the Company is no 2015, 2017 may On December 22, 2017, 1, 2018 ” ("Ta x January 1, 2018, not
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers an d directors based on the estimated fair values of the awards as of the grant date. The Company records the value of the portion of the award that is ultimately expected to vest as expense over the requisite service period. The Company also accounts for equity instruments issued to non-employees using a fair value approach under Accounting Standards Codification ("ASC") subtopic 505 50 . The Company values equity instruments and stock options granted using the Black-Scholes option pricing model.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss per Share of Common Stock The Company uses the two entitle the holders to participate in dividends and earnings of the Company. The two
Segment Reporting, Policy [Policy Text Block]	Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) for which discrete financial information is ava ilable and regularly reviewed by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company views its operations and manages its business as a single operating and reporting segment. The Company holds assets in both the United States and Europe as of December 31, 2022 2021
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency Assets and liabilities are translated into the reporting currency using the exchange rates in effect on the consolidated balance sheet dates. Equity accounts are translated at historical rates, except for the change in retained earnings during the year, which is the result of the income statement translation process. Revenue and expense accounts are translated using the weighted average exchange rate during the period. The cumulative translation adjustments associated with the net assets of foreign subsidiaries are recorded in accumulated other comprehensive income/loss in the accompanying consolidated statements of stockholders’ equity.
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards — Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In August 2020, No. 2020 06, Debt Debt with Conversion and Other Options (Subtopic 470 20 and Derivatives and Hedging Contracts in Entity s Own Equity (Subtopic 815 40 Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06” December 15, 2021, 2020 06 not In May 2021, No. 2021 04, Earnings Per Share (Topic 260 Modifications and Extinguishments (Subtopic 470 50 Stock Compensation (Topic 718 Contracts in Entity s Own Equity (Subtopic 815 40 s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, a consensus of the FASB Emerging Issues Task Force 2021 04” December 15, 2021, 2021 04 not

Note A - Description of Busin_2

Note A - Description of Business, Basis of Presentation, and Significant Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Asset Acquisition [Table Text Block]	Cash $ 12,800 Assumed reserve liability 5,200 Total consideration $ 18,000 Total consideration 18,000 Direct transaction costs associated with the acquisition (1) 1,290 Total purchase price to be allocated $ 19,290 Property and equipment, inventory and assembled workforce acquired 1,627 IPR&D (2) 17,663 Total allocated purchase price $ 19,290

Note C - Accounts and Other R_2

Note C - Accounts and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, 2022 2021 Accounts receivable $ 7,185 $ 1,421 Other receivables 1,114 107 Total accounts and other receivables $ 8,299 $ 1,528

Note D - Prepaid Expenses and_2

Note D - Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, 2022 2021 Prepaid insurance $ 577 $ 637 Prepaid offering costs - 293 Other prepaid expenses and current assets 1,300 252 Total prepaid expenses and other current assets $ 1,877 $ 1,182

Note E - Property and Equipme_2

Note E - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, 2022 2021 Laboratory equipment $ 710 $ 645 Furniture and office equipment 104 71 Computers and hardware 462 338 Leasehold improvements 710 724 Finance lease right-of-use assets 251 1,031 Total property and equipment 2,237 2,809 Less: accumulated depreciation and amortization (1,443 ) (1,925 ) Property and equipment, net $ 794 $ 884
Property, Plant and Equipment, Useful Life [Table Text Block]	Useful Life Asset Category (in years) Laboratory equipment 10 Furniture and office equipment 5 - 10 Computers and hardware 3 - 7 Leasehold improvements 9

Note F - Accounts Payable and_2

Note F - Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, 2022 2021 Accrued banking fees - 700 Accrued payroll 1,673 1,054 Accrued professional fees 256 259 Accounts payable 3,611 516 Other accrued expenses 629 509 Total accounts payable and accrued expenses $ 6,169 $ 3,038

Note J - Common Stock and War_2

Note J - Common Stock and Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]	December 31, 2022 2021 Outstanding awards under equity incentive plans 2,456,407 1,273,879 Outstanding common stock warrants 4,252,600 4,252,600 Possible future issuances under equity incentive plans 4,421,508 4,209,935 Possible future issuances under employee stock purchase plan 1,417,365 1,500,000 Total common shares reserved for future issuance 12,547,880 11,236,414
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Shares of Common Stock Balance as of January 1, 2021 4,537,321 Common stock issued as a result of the Public Offering 7,139,498 Common stock issued as a result of Series B-2 Preferred Stock conversions 4,842,699 Common stock issued as a result of warrant exercises 18,772,510 Common stock issued as compensation to third-parties 35,129 Adjustment for cash paid in lieu of DTC fractional shares (1,356 ) Common stock repurchased as a result of the Stock Repurchase Program (320,161 ) Balance as of December 31, 2021 35,005,640 Common stock issued as compensation to third-parties 41,821 Common stock repurchased as a result of the Stock Repurchase Program (589,792 ) Common stock issued as a result of the Employee Stock Purchase Plan 82,635 Balance as of December 31, 2022 34,540,304

Note K - Stock-based Compensa_2

Note K - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Year ended December 31, 2022 2021 Research and development $ 1,443 $ 914 General and administrative 2,851 1,522 Total stock-based compensation expense $ 4,294 $ 2,436
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended December 31, 2022 2021 Risk-free interest rate 1.70% - 3.80% 0.92% - 1.55% Expected term (in years) 5.50 - 7.00 5.50 - 10.00 Expected volatility 91.28% - 98.91% 96.91% - 102.57% Expected dividend yield 0 0
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Avg Aggregate Number of Average Remaining Intrinsic Options Exercise Price Contractual Term Value Outstanding balance at January 1, 2022 1,273,879 $ 27.58 8.73 $ 254,207 Granted 1,434,245 $ 6.32 Exercised or released - $ - Canceled or forfeited 245,593 $ 9.23 $ 74,033 Expired 6,124 $ 93.60 Outstanding balance at December 31, 2022 2,456,407 $ 16.84 8.51 $ 11,819 Exercisable at December 31, 2022 615,001 $ 44.52 6.99 $ 2,722 Vested and expected to vest at December 31, 2022 2,375,700 $ 17.15 8.49 $ 11,628
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Avg Weighted Avg Number of Remaining Number of Remaining Exercise Price Shares Contractual Term Shares Contractual Term $2.848 to $10.00 2,175,436 8.90 351,151 8.19 $10.01 to $30.00 69,375 8.17 69,375 8.17 $30.01 to $50.00 68,514 6.11 51,393 6.11 $50.01 to $70.00 41,866 4.08 41,866 4.08 $70.01 to $327.20 101,216 3.70 101,216 3.70 2,456,407 8.51 615,001 6.99
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Number of Unvested Options December 31, Exercise Price 2022 2021 $2.848 to $10.00 1,824,285 861,139 $10.01 to $30.00 - 60,000 $30.01 to $50.00 17,121 36,190 $50.01 to $70.00 - - $70.01 to $327.20 - 9,335 Total number of unvested stock options 1,841,406 966,664

Note L - Fair Value of Financ_2

Note L - Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Quoted Prices Significant in Active Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2022 (Level 1) (Level 2) (Level 3) OTA Warrant liability $ 1 $ - $ - $ 1 Total liabilities $ 1 $ - $ - $ 1 Securities: U.S. government-sponsored agency securities $ 7,189 $ - $ 7,189 $ - U.S. Treasury securities 9,711 9,711 - - Total assets $ 16,900 $ 9,711 $ 7,189 $ - Quoted Prices Significant in Active Other Significant Balance at Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2021 (Level 1) (Level 2) (Level 3) OTA Warrant liability $ 288 $ - $ - $ 288 Embedded Warrant Put Option 18 - - 18 KVK Warrant liability 24 - 24 - Total liabilities $ 330 $ - $ 24 $ 306
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	2022 2021 Balance as of beginning of period $ 306 $ 255 Adjustment to fair value (305 ) 51 Balance as of end of period $ 1 $ 306

Note M - Income Taxes (Tables)

Note M - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended December 31, 2022 2021 Federal statutory rate 21.00 % 21.00 % Effect of: Change in valuation allowance (22.06 ) (28.39 ) Return to provision and deferred true-up (3.41 ) (0.26 ) Federal research and development credit 1.16 - State research and development credit 0.07 - Change in rate 0.51 3.00 State tax benefit (net of federal) 3.03 5.14 Warrant liability 0.16 (0.06 ) Stock-based compensation (0.69 ) (2.68 ) PPP Loan forgiveness - 1.94 Global intangible low-taxed income credit (1.22 ) - Foreign research and development excess benefit 3.16 - Other 0.15 (0.08 ) Federal income tax provision effective rate 1.86 % (0.39 )%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2022 2021 Deferred tax assets relating to: Net operating loss carryforwards $ 66,373 $ 60,977 Research and development tax carryforward 6,900 6,411 Stock-based compensation 4,185 4,807 174 expenses 3,730 - Right-of-use liability 359 424 Property and equipment 22 14 Other deferred tax assets 598 288 Total gross deferred tax assets 82,167 72,921 Deferred tax liabilities relating to: Right-of-use asset (336 ) (401 ) Other deferred tax liabilities - (9 ) Total gross deferred tax liabilities (336 ) (410 ) Deferred tax assets less liabilities 81,831 72,511 Valuation allowance (81,831 ) (72,511 ) Net deferred tax asset (liability) $ - $ -

Note N - Net Loss Per Share (Ta

Note N - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	December 31, 2022 2021 Awards under equity incentive plans 2,456,407 1,273,879 Common stock warrants 4,252,600 4,221,350 Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 6,709,007 5,495,229
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	December 31, 2022 2021 Basic and diluted net loss per share of common stock: Net loss $ (41,543 ) $ (8,555 ) Less: Dividends declared or accumulated - (54,342 ) Net loss attributable to common stockholders $ (41,543 ) $ (62,897 ) Less: Net loss attributable to participating securities $ - $ - Undistributed net loss attributable to shares of common stockholders, basic and diluted $ (41,543 ) $ (62,897 ) Weighted average number of shares of common stock outstanding, basic and diluted 34,489 29,766 Basic and diluted net loss attributable to common stockholders per share of common stock $ (1.20 ) $ (2.11 )

Note O - Leases (Tables)

Note O - Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Notes Tables
Lease, Cost [Table Text Block]	Year Ended December 31, Lease Cost 2022 2021 Finance lease cost: Amortization of right-of-use assets $ 129 $ 129 Interest on lease liabilities 2 9 Total finance lease cost 131 138 Operating lease cost 418 365 Short-term lease cost 210 199 Variable lease cost 39 47 Less: sublease income (157 ) (91 ) Total lease costs $ 641 $ 658
Schedule of Leases Cash Flow Information [Table Text Block]	Year Ended December 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 2 $ 9 Financing cash flows from finance leases 16 173 Operating cash flows from operating leases 522 460 Operating cash flows from short-term leases 210 199 Operating cash flows from variable lease costs 39 47 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ - $ - Operating leases 123 -
Schedule of Leases Balance Sheet Information [Table Text Block]	December 31, 2022 2021 Finance Leases Property and equipment, at cost $ 1,031 $ 1,031 less: accumulated depreciation and amortization (780 ) (651 ) Property and equipment, net $ 251 $ 380 Other current liabilities $ 6 $ 15 Other long-term liabilities - 6 Total finance lease liabilities $ 6 $ 21 Operating Leases Operating lease right-of-use assets $ 988 $ 1,141 Total operating lease right-of-use assets $ 988 $ 1,141 Current portion of operating lease liabilities $ 480 $ 356 Operating lease liabilities, less current portion 843 1,232 Total operating lease liabilities $ 1,323 $ 1,588 Weighted Average Remaining Lease Term Finance leases 1 year 1 year Operating leases 3 years 4 years Weighted Average Discount Rate Finance leases 14.3 % 12.0 % Operating leases 7.3 % 7.5 %
Operating and Finance Lease, Liability, Maturity [Table Text Block]	Finance Operating Year Ending December 31, Leases Leases 2023 $ 7 $ 563 2024 - 488 2025 - 389 2026 - 30 2027 - - Thereafter - - Total lease payments 7 1,470 Less: future interest expense (1 ) (147 ) Lease liabilities $ 6 $ 1,323

Note A - Description of Busin_3

Note A - Description of Business, Basis of Presentation, and Significant Transactions (Details Textual) - USD ($) $ / shares in Units, $ in Thousands							12 Months Ended
		May 15, 2022	Jul. 12, 2021	Feb. 01, 2021	Jan. 12, 2021	Jan. 08, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 20, 2021	Jul. 02, 2021	Feb. 03, 2021
Sale of Stock, Authorized Amount			$ 350,000
Stock Repurchase Program, Authorized Amount									$ 50,000
Treasury Stock, Value, Total							$ 7,536	$ 2,814
Share Repurchase Program [Member]
Treasury Stock, Shares, Total (in shares)							909,953
Treasury Stock, Value, Total							$ 7,500
Roth Capital Partners, LLC [Member] | Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					926,844	926,844
Roth Capital Partners, LLC [Member] | Public Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					12,078,361	7,692,307
Class of Warrant or Right, Offering Price, Per Related Warrant (in dollars per share)						$ 0.0001
Roth Capital Partners, LLC [Member] | Underwriter Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					806,932	754,035					18,702
Over Allotment Options, Number of Shares for Warrants (in shares)						1,153,846
Underwriting Agreement [Member] | Roth Capital Partners, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)						6,765,463
Shares and Warrants Issued, Price Per Share (in dollars per share)						$ 6.50
Shares Issued, Price Per Share (in dollars per share)						$ 6.4999
Proceeds from Issuance or Sale of Equity, Total					$ 52,400
Over-Allotment Option [Member] | Roth Capital Partners, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)				374,035
Purchase Agreement Optional Period to Shares (Day)						45 days
Purchase Agreement, Maximum, Additional Shares Available for Purchase During the Optional Period (in shares)						1,153,846
ATM Agreement Sales [Member] | JMP and RBCCM [Member]
Stock Issued During Period, Shares, New Issues (in shares)							0	0
Equity Distribution Agreement, Maximum Aggregate Offering Price										$ 75,000
Equity Distribution Agreement, Commission Fee, Percentage of Gross Sales										3%
Stock Issued During Period, Value, New Issues			$ 75,000
Arimoclomol Purchase Agreement [Member]
Payments to Acquire Productive Assets, Total		$ 12,800
Asset Acquisition, Consideration Transferred, Estimated Reserve Liability		$ 5,200					$ 9,000
Estimated Weighted Average Cost of Capital		42%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount							$ 800
Arimoclomol Purchase Agreement [Member] | In Process Research and Development [Member]
Asset Acquisition, Recognized Identifiable Assets, Finite-Lived Intangibles	[1]	$ 17,663
[1]The primary asset acquired, the IPR&D asset, was expensed and the allocated transaction related costs were included with and expensed with this asset.

Note A - Description of Busin_4

Note A - Description of Business, Basis of Presentation, and Significant Transactions - Consideration Paid and Purchase Price Allocation for the Acquisition of Arimoclomol (Details) - Arimoclomol Purchase Agreement [Member] - USD ($) $ in Thousands			12 Months Ended
		May 15, 2022	Dec. 31, 2022
Cash		$ 12,800
Assumed reserve liability		5,200	$ 9,000
Total consideration		18,000
Total consideration		18,000
Direct transaction costs associated with the acquisition (1)	[1]	1,290
Total purchase price to be allocated		19,290
Property and equipment, inventory and assembled workforce acquired		1,627
Total allocated purchase price		19,290
In Process Research and Development [Member]
IPR&D (2)	[2]	$ 17,663
[1]As a result of the asset acquisition accounting, the transaction costs associated with the acquisition should be included in the costs of the assets acquired and allocated amongst qualifying assets using the relative fair value basis. The transaction costs primarily included financial advisor fees and legal expenses.[2]The primary asset acquired, the IPR&D asset, was expensed and the allocated transaction related costs were included with and expensed with this asset.

Note B - Summary of Significa_2

Note B - Summary of Significant Accounting Policies (Details Textual)					3 Months Ended	12 Months Ended
	May 15, 2022 USD ($)	May 07, 2021 USD ($)	Mar. 02, 2021 USD ($)	Mar. 20, 2012	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2020 USD ($)
Investments, Fair Value Disclosure, Total						$ 16,900,000	$ 14,900,000
Unrealized Gain (Loss) on Investments						(577,000)	(13,000)
Certificates of Deposit, at Carrying Value						20,500,000	500,000
Impairment, Long-Lived Asset, Held-for-Use, Total						0	0
Revenue from Contract with Customer, Including Assessed Tax						10,458,000	28,650,000
Inventory, Noncurrent, Total						671,000	0
Income Tax Examination, Penalties and Interest Accrued						$ 0	0
Income tax returns under examination						0
Pre-launch Inventory that Qualified for Capitalization [Member]
Inventory, Net, Total						$ 0	0
Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax						100,000	100,000
Deferred Revenue, Total						0	0
GPC Member | License [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 10,000,000	$ 10,000,000
Revenue Recognition, Milestone Method, Additional Revenue to be Recognized		$ 590,000,000
Deferred Revenue, Total						0	0
Aquestive Therapeutics [Member] | License [Member]
Revenue from Contract with Customer, Including Assessed Tax						900,000	20,900,000
Royalty Revenue, Percent				10%
Corium, Inc [Member] | Consulting Services [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 2,000,000	4,700,000	7,700,000
Deferred Revenue, Total						0	$ 400,000
Consulting Agreement, Maximum Amount to be Received								$ 15,600,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total								13,600,000
Consulting Agreement, Conditional Milestone Achievement to be Received								$ 2,000,000
Arimoclomol Purchase Agreement [Member]
Contract with Customer, Liability, Revenue Recognized						4,800,000
Contract with Customer, Clawback Liability						3,800,000
Asset Acquisition, Consideration Transferred, Estimated Reserve Liability	$ 5,200,000					$ 9,000,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)						3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)						10 years

Note C - Accounts and Other R_3

Note C - Accounts and Other Receivables - Accounts and Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts receivable	$ 7,185	$ 1,421
Other receivables	1,114	107
Total accounts and other receivables	$ 8,299	$ 1,528

Note D - Prepaid Expenses and_3

Note D - Prepaid Expenses and Other Current Assets - Components of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Prepaid insurance	$ 577	$ 637
Prepaid offering costs	0	293
Other prepaid expenses and current assets	1,300	252
Total prepaid expenses and other current assets	$ 1,877	$ 1,182

Note E - Property and Equipme_3

Note E - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Depreciation, Depletion and Amortization, Total	$ 944,000	$ 257,000
Property and Equipment, Including Finance Leases [Member]
Depreciation, Depletion and Amortization, Total	$ 298,000	$ 257,000

Note E - Property and Equipme_4

Note E - Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property and equipment, gross	$ 2,237	$ 2,809
Less: accumulated depreciation and amortization	(1,443)	(1,925)
Property and equipment, net	794	884
Laboratory Equipment [Member]
Property and equipment, gross	710	645
Furniture and Fixtures [Member]
Property and equipment, gross	104	71
Computer and Hardware [Member]
Property and equipment, gross	462	338
Leasehold Improvements [Member]
Property and equipment, gross	710	724
Finance Lease, Right-of-Use Assets [Member]
Property and equipment, gross	$ 251	$ 1,031

Note E - Property and Equipme_5

Note E - Property and Equipment - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Laboratory Equipment [Member]
Property and equipment, useful lives (Year)	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property and equipment, useful lives (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property and equipment, useful lives (Year)	10 years
Computer and Hardware [Member] | Minimum [Member]
Property and equipment, useful lives (Year)	3 years
Computer and Hardware [Member] | Maximum [Member]
Property and equipment, useful lives (Year)	7 years
Leasehold Improvements [Member]
Property and equipment, useful lives (Year)	9 years

Note F - Accounts Payable and_3

Note F - Accounts Payable and Accrued Expenses - Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accrued banking fees	$ 0	$ 700
Accrued payroll	1,673	1,054
Accrued professional fees	256	259
Accounts payable	3,611	516
Other accrued expenses	629	509
Total accounts payable and accrued expenses	$ 6,169	$ 3,038

Note G - Debt Obligations (Deta

Note G - Debt Obligations (Details Textual) - USD ($) $ in Millions

12 Months Ended

Jan. 31, 2023

Jan. 26, 2023

May 31, 2022

Feb. 08, 2021

Jan. 12, 2021

Jan. 01, 2021

Apr. 23, 2020

Jan. 13, 2020

Dec. 18, 2019

Jun. 02, 2014

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Jun. 30, 2016

Feb. 09, 2016

Certificates of Deposit, at Carrying Value

$ 20.5

$ 0.5

Wells Fargo Bank, N.A. [Member] | Subsequent Event [Member]

Debt Instrument, Face Amount

$ 12.8

Wells Fargo Bank, N.A. [Member] | Prime Rate [Member] | Subsequent Event [Member]

Debt Instrument, Basis Spread on Variable Rate

2.25%

December 2020 Exchange Agreement [Member]

Debt Conversion, Original Debt, Amount

$ 31.5

Debt Conversion, Converted Instrument, Shares Issued (in shares)

31,476.98412

Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)

3,632,019

2021 Notes [Member]

Debt Instrument, Face Amount

$ 86.3

Debt Instrument, Interest Rate, Stated Percentage

5.50%

Debt Instrument, Cancellation of Debt, Amount

$ 3

$ 71.4

The 2019 Notes [Member]

Debt Instrument, Face Amount

$ 71.4

Debt Instrument, Interest Rate, Stated Percentage

6.75%

January 2020 Note [Member]

Debt Instrument, Face Amount

$ 3

The December 2020 Exchange Agreement [Member]

Repayments of Debt

$ 30.3

The December 2019 and January 2020 Notes [Member]

Long-term Debt, Gross

$ 60.8

Deerfield Facility Agreement [Member]

Long-term Debt, Gross

$ 7.5

The Facility Notes [Member]

Debt Instrument, Interest Rate, Stated Percentage

6.75%

Long-term Debt, Total

$ 7.6

Repayments of Long-term Debt, Total

$ 30.3

Paycheck Protection Program CARES Act [Member]

Proceeds from Issuance of Long-term Debt, Total

$ 0.8

Deerfield Facility Agreement [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 60

Line of Credit Facility, Interest Rate at Period End

9.75%

6.75%

Repayments of Long-term Debt, Total

$ 8

Deerfield Facility Agreement [Member] | Series D Redeemable Convertible Preferred Stock [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

14,423,076

Deerfield Facility Agreement [Member] | Term Notes [Member]

Proceeds from Secured Notes Payable

$ 15

Deerfield Facility Agreement [Member] | Deerfield Convertible Notes [Member]

Proceeds from Secured Notes Payable

$ 10

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)

120,192

Revolving Credit Facility [Member] | Ameris Bank [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 20

20

Proceeds from Lines of Credit, Total

12.8

Certificates of Deposit, at Carrying Value

12.8

Line of Credit Facility, Remaining Borrowing Capacity

$ 7.2

Revolving Credit Facility [Member] | Ameris Bank [Member] | Subsequent Event [Member]

Repayments of Lines of Credit

$ 12.8

Revolving Credit Facility [Member] | Ameris Bank [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]

Debt Instrument, Basis Spread on Variable Rate

1.60%

Debt Instrument, SOFR Floor on Basis Spread of Variable Rate

0%

Note H - Commitments and Cont_2

Note H - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Loss Contingency Accrual, Ending Balance	$ 0	$ 0

Note I - Preferred Stock and _2

Note I - Preferred Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended	12 Months Ended
	Jan. 12, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2022
Preferred Stock, Shares Authorized (in shares)			10,000,000	10,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)			0	0
Preferred Stock, Shares Issued (in shares)			0	0
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Conversion of Stock, Shares Issued (in shares)		4,842,699	4,842,699
The Facility Notes [Member]
Repayments of Long-term Debt, Total	$ 30.3
Series B-2 Convertible Preferred Stock [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)	4,842,690
Preferred Stock, Convertible, Conversion Price (in dollars per share)	$ 6.4999
December 2020 Exchange Agreement [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,476.98412
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)	3,632,019
Debt Conversion, Original Debt, Amount	$ 31.5

Note J - Common Stock and War_3

Note J - Common Stock and Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	6 Months Ended	12 Months Ended
	Jan. 26, 2021	Jan. 12, 2021	Oct. 25, 2018	Jun. 02, 2014	Jan. 31, 2021	Jun. 18, 2021	Dec. 31, 2022	Dec. 31, 2021	Feb. 03, 2021	Jan. 08, 2021	Dec. 31, 2020
Common Stock, Shares Authorized (in shares)							250,000,000	250,000,000
Common Stock, Shares, Issued (in shares)							35,450,257	35,325,801
Common Stock, Shares, Outstanding, Ending Balance (in shares)							34,540,304	35,005,640			4,537,321
Stock Issued During Period, Shares, Warrant Exercises (in shares)								18,772,510
Proceeds from Warrant Exercises							$ 0	$ 30,819
Preferred Stock Dividends and Other Adjustments, Total							$ 0	54,342
OTA Warrant [Member]
Class of Warrant or Right Issued (in shares)				14,423,076
OTA Warrant [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				1,923,077							120,192
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 46.25			$ 5.85		$ 38.34					$ 93.60
Warrant Issued to KVK [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			31,250								31,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.30								$ 36.80
Class of Warrant or Right, Additional Shares Exercisable for Each Milestones (in shares)			7,812.5
Pre-funded Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		926,844								926,844
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.0001
Stock Issued During Period, Shares, Warrant Exercises (in shares)					926,841
Proceeds from Warrant Exercises					$ 72,000
Public Offering Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		12,078,361								7,692,307
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.50
Stock Issued During Period, Shares, Warrant Exercises (in shares)							3,030,881
Proceeds from Warrant Exercises							$ 16,900
Warrants and Rights Outstanding, Term (Year)		5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise		4.99%
Class of Warrants or Right, Exercised During Period (in shares)							3,461,858
Underwriter Warrants [Member] | Roth Capital Partners, LLC [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		806,932							18,702	754,035
Stock Issued During Period, Shares, Warrant Exercises (in shares)							400,000
Proceeds from Warrant Exercises							$ 3,300
Class of Warrants or Right, Exercised During Period (in shares)							400,000
Over Allotment Options, Percentage of Common Stock Outstanding for Warrants		5%
Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,620,358
Proceeds from Warrant Exercises	$ 44,000
Placement Agent Fee, Percentage	6%
January 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	7,944,430					6,117,509
Stock Issued During Period, Shares, Warrant Exercises (in shares)							1,676,921
Proceeds from Warrant Exercises						$ 39,100	$ 10,700
Warrants and Rights Outstanding, Term (Year)	5 years
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise	4.99%
Class of Warrants or Right, Exercised During Period (in shares)							1,676,921
Placement Agent Fee, Percentage						6%
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection	9.99%
Preferred Stock Dividends and Other Adjustments, Total								$ 37,400
June 2021 Inducement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,529,379
Maximum Percent of Common Stock Ownership Allowed Per Holder Upon Warrant Exercise						4.99%
Class of Warrants or Right, Exercised During Period (in shares)							0	0
Maximum Percent of Common Stock Ownership Allowed Per Holder After Warrant Exercise Upon Holders Selection						9.99%
Preferred Stock Dividends and Other Adjustments, Total								$ 16,900

Note J - Common Stock and War_4

Note J - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Common shares reserved for future issuance (in shares)	12,547,880	11,236,414
Warrant [Member]
Common shares reserved for future issuance (in shares)	4,252,600	4,252,600
Share-Based Payment Arrangement [Member]
Common shares reserved for future issuance (in shares)	2,456,407	1,273,879
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	4,421,508	4,209,935
Possible Future Issuances Under Employee Stock Purchase Plans [Member]
Common shares reserved for future issuance (in shares)	1,417,365	1,500,000

Note J - Common Stock and War_5

Note J - Common Stock and Warrants - Common Stock Activity (Details) - shares	1 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Balance (in shares)		35,005,640	4,537,321
Common stock issued as a result of warrant exercises (in shares)			18,772,510
Common stock issued as compensation to third-parties (in shares)		41,821	35,129
Adjustment for cash paid in lieu of DTC fractional shares (in shares)			(1,356)
Common stock repurchased as a result of the Stock Repurchase Program (in shares)		(589,792)	(320,161)
Common stock issued as a result of the Employee Stock Purchase Plan (in shares)		82,635
Balance (in shares)		34,540,304	35,005,640
Conversion of Series B-2 Preferred Stock into Common Stock [Member]
Common stock issued as a result of Series B-2 Preferred Stock conversions (in shares)	4,842,699		4,842,699
Underwritten Public Offering [Member]
Common stock issued as a result of the Public Offering (in shares)			7,139,498

Note K - Stock-based Compensa_3

Note K - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Jan. 01, 2023	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Jan. 31, 2023
Employee Stock Purchase Plan, Maximum Number of Issuable Shares (in shares)		1,500,000
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)			82,635
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0%	0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)			$ 5.01	$ 7.53
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value			$ 3,700	$ 2,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 8,200
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			2 years 9 months 25 days
Share-based Payment Arrangement, Expense			$ 4,294	2,436
Performance Shares [Member]
Share-based Payment Arrangement, Expense			$ 400	$ 400
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		4,900,000,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			6,889,885
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding		4%
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)			0	0
2014 Equity Incentive Plan [Member] | Subsequent Event [Member]
Increase in Common Stock Reserved for Issuance (in shares)	1,381,612
The 2023 Plan [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)					1,500,000

Note K - Stock-based Compensa_4

Note K - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock based compensation expense	$ 4,294	$ 2,436
Research and Development Expense [Member]
Stock based compensation expense	1,443	914
General and Administrative Expense [Member]
Stock based compensation expense	$ 2,851	$ 1,522

Note K - Stock-based Compensa_5

Note K - Stock-based Compensation - Black-Scholes Option-pricing Model (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Expected dividend yield	0%	0%
Minimum [Member]
Risk-free interest rate	1.70%	0.92%
Expected term (in years) (Year)	5 years 6 months	5 years 6 months
Expected volatility	91.28%	96.91%
Maximum [Member]
Risk-free interest rate	3.80%	1.55%
Expected term (in years) (Year)	7 years	10 years
Expected volatility	98.91%	102.57%

Note K - Stock-based Compensa_6

Note K - Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Outstanding, number of options (in shares)	1,273,879
Outstanding, weighted average exercise price (in dollars per share)	$ 27.58
Outstanding, weighted average remaining contractual term (Year)	8 years 6 months 3 days	8 years 8 months 23 days
Outstanding, aggregate intrinsic value	$ 11,819	$ 254,207
Granted, number of options (in shares)	1,434,245
Granted, weighted average exercise price (in dollars per share)	$ 6.32
Exercised or released, number of options (in shares)	0
Exercised or released, weighted average exercise price (in dollars per share)	$ 0
Canceled or forfeited, number of options (in shares)	245,593
Canceled or forfeited, weighted average exercise price (in dollars per share)	$ 9.23
Canceled or forfeited, aggregate intrinsic value	$ 74,033
Expired, number of options (in shares)	6,124
Expired, weighted average exercise price (in dollars per share)	$ 93.60
Outstanding, number of options (in shares)	2,456,407	1,273,879
Outstanding, weighted average exercise price (in dollars per share)	$ 16.84	$ 27.58
Exercisable, number of options (in shares)	615,001
Exercisable, weighted average exercise price (in dollars per share)	$ 44.52
Exercisable, weighted average remaining contractual term (Year)	6 years 11 months 26 days
Exercisable, aggregate intrinsic value	$ 2,722
Vested and expected to vest, number of options (in shares)	2,375,700
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 17.15
Vested and expected to vest, weighted average remaining contractual term (Year)	8 years 5 months 26 days
Vested and expected to vest, aggregate intrinsic value	$ 11,628

Note K - Stock-based Compensa_7

Note K - Stock-based Compensation - Information Regarding Currently Outstanding and Exercisable Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Options outstanding, number of shares (in shares)	2,456,407	1,273,879
Outstanding, weighted average remaining contractual term (Year)	8 years 6 months 3 days	8 years 8 months 23 days
Exercisable, number of options (in shares)	615,001
Exercisable, weighted average remaining contractual term (Year)	6 years 11 months 26 days
Exercise Price Range One [Member]
Lower range (in dollars per share)	$ 2.848
Upper range (in dollars per share)	$ 10
Options outstanding, number of shares (in shares)	2,175,436
Outstanding, weighted average remaining contractual term (Year)	8 years 10 months 24 days
Exercisable, number of options (in shares)	351,151
Exercisable, weighted average remaining contractual term (Year)	8 years 2 months 8 days
Exercise Price Range Two [Member]
Lower range (in dollars per share)	$ 10.01
Upper range (in dollars per share)	$ 30
Options outstanding, number of shares (in shares)	69,375
Outstanding, weighted average remaining contractual term (Year)	8 years 2 months 1 day
Exercisable, number of options (in shares)	69,375
Exercisable, weighted average remaining contractual term (Year)	8 years 2 months 1 day
Exercise Price Range Three [Member]
Lower range (in dollars per share)	$ 30.01
Upper range (in dollars per share)	$ 50
Options outstanding, number of shares (in shares)	68,514
Outstanding, weighted average remaining contractual term (Year)	6 years 1 month 9 days
Exercisable, number of options (in shares)	51,393
Exercisable, weighted average remaining contractual term (Year)	6 years 1 month 9 days
Exercise Price Range Four [Member]
Lower range (in dollars per share)	$ 50.01
Upper range (in dollars per share)	$ 70
Options outstanding, number of shares (in shares)	41,866
Outstanding, weighted average remaining contractual term (Year)	4 years 29 days
Exercisable, number of options (in shares)	41,866
Exercisable, weighted average remaining contractual term (Year)	4 years 29 days
Exercise Price Range Five [Member]
Lower range (in dollars per share)	$ 70.01
Upper range (in dollars per share)	$ 327.20
Options outstanding, number of shares (in shares)	101,216
Outstanding, weighted average remaining contractual term (Year)	3 years 8 months 12 days
Exercisable, number of options (in shares)	101,216
Exercisable, weighted average remaining contractual term (Year)	3 years 8 months 12 days

Note K - Stock-based Compensa_8

Note K - Stock-based Compensation - Nonvested Stock Option Awards (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020
Number of unvested shares (in shares)	1,841,406	966,664
Exercise Price Range One [Member]
Lower range (in dollars per share)	$ 2.848
Number of unvested shares (in shares)	1,824,285	861,139
Exercise Price Range Two [Member]
Lower range (in dollars per share)	$ 10.01
Number of unvested shares (in shares)	0	60,000
Exercise Price Range Three [Member]
Lower range (in dollars per share)	$ 30.01
Number of unvested shares (in shares)	17,121	36,190
Exercise Price Range Four [Member]
Lower range (in dollars per share)	$ 50.01
Number of unvested shares (in shares)	0	0
Exercise Price Range Five [Member]
Lower range (in dollars per share)	$ 70.01
Number of unvested shares (in shares)	0	9,335

Note L - Fair Value of Financ_3

Note L - Fair Value of Financial Instruments (Details Textual)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
OTA Warrant [Member]
Liabilities, Fair Value Disclosure, Total	$ 1,000	$ 288,000
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Liquidity Event	30,000,000
Liabilities, Fair Value Disclosure, Estimated Amount of Weighted-average Probability of Fundamental Change	$ 379,000,000
OTA Warrant [Member] | Weighted Average Probability of Liquidity Event [Member]
Derivative Liability, Measurement Input	0.25
OTA Warrant [Member] | Weighted Average Probability of Fundamental Change [Member]
Derivative Liability, Measurement Input	0.28
Embedded Put Option [Member]
Liabilities, Fair Value Disclosure, Total	$ 0	$ 18,000

Note L - Fair Value of Financ_4

Note L - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Financial liabilities measured at fair value on recurring basis	$ 1	$ 330
Total assets	16,900
US Government Agencies Debt Securities [Member]
Total assets	7,189
US Treasury Securities [Member]
Total assets	9,711
Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
Total assets	9,711
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Total assets	0
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Total assets	9,711
Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	0	24
Total assets	7,189
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Total assets	7,189
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Total assets	0
Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	1	306
Total assets	0
Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Total assets	0
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Total assets	0
OTA Warrant [Member]
Financial liabilities measured at fair value on recurring basis	1	288
OTA Warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
OTA Warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	0	0
OTA Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	$ 1	288
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis		18
Embedded Put Option [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis		0
Embedded Put Option [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis		0
Embedded Put Option [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis		18
KVK Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis		24
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis		0
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis		24
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis		$ 0

Note L - Fair Value of Financ_5

Note L - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance as of beginning of period	$ 306	$ 255
Adjustment to fair value	(305)	51
Balance as of end of period	$ 1	$ 306

Note M - Income Taxes (Details

Note M - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	$ 31,000	$ 34,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total	(42,329,000)	(8,521,000)
Deferred Tax Assets, Tax Credit Carryforwards, Research	6,900,000	6,411,000
Foreign Tax Authority [Member] | Danish [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	800,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	236,000,000
Operating Loss Carryforwards, Subject to Expiration	$ 138,100,000	$ 225,200,000
Operating Loss Carryforwards, Expiration, Beginning Year	2027	2027
Operating Loss Carryforwards, Not Subject to Expiration	$ 97,900,000

Note M - Income Taxes - Schedul

Note M - Income Taxes - Schedule of Reconciliation of Difference Between Benefit for Income Taxes and Income Taxes at Statutory U.S. Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Federal statutory rate	21%	21%
Change in valuation allowance	(22.06%)	(28.39%)
Return to provision and deferred true-up	(3.41%)	(0.26%)
Change in rate	0.51%	3%
Warrant liability	0.16%	(0.06%)
Stock-based compensation	(0.69%)	(2.68%)
PPP Loan forgiveness	0%	1.94%
Global intangible low-taxed income credit	(1.22%)	0%
Other	0.15%	(0.08%)
Federal income tax provision effective rate	1.86%	(0.39%)
Domestic Tax Authority [Member]
Research and development credit	1.16%	0%
State and Local Jurisdiction [Member]
Research and development credit	0.07%	0%
Foreign Tax Authority [Member]
Research and development credit	3.16%	0%

Note M - Income Taxes - Compone

Note M - Income Taxes - Components of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Net operating loss carryforwards	$ 66,373	$ 60,977
Deferred Tax Assets, Tax Credit Carryforwards, Research	6,900	6,411
Stock-based compensation	4,185	4,807
174 expenses	3,730	0
Right-of-use liability	359	424
Property and equipment	(22)	(14)
Other deferred tax assets	598	288
Total gross deferred tax assets	82,167	72,921
Right-of-use asset	(336)	(401)
Other deferred tax liabilities	0	(9)
Total gross deferred tax liabilities	(336)	(410)
Deferred tax assets less liabilities	81,831	72,511
Valuation allowance	(81,831)	(72,511)
Net deferred tax asset (liability)	$ 0	$ 0

Note N - Net Loss Per Share - A

Note N - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive securities (in shares)	6,709,007	5,495,229
Share-Based Payment Arrangement [Member]
Antidilutive securities (in shares)	2,456,407	1,273,879
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	4,252,600	4,221,350

Note N - Net Loss Per Share - E

Note N - Net Loss Per Share - Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Net loss	$ (41,543)	$ (8,555)
Less: Dividends declared or accumulated	0	(54,342)
Net loss attributable to common stockholders	(41,543)	(62,897)
Less: Net loss attributable to participating securities	0	0
Undistributed net loss attributable to shares of common stockholders, basic and diluted	$ (41,543)	$ (62,897)
Weighted average number of shares of common stock outstanding, basic and diluted (in shares)	34,488,800	29,766,347
Basic and diluted net loss attributable to common stockholders per share of common stock (in dollars per share)	$ (1.20)	$ (2.11)

Note O - Leases (Details Textua

Note O - Leases (Details Textual)	12 Months Ended
	Dec. 31, 2022
Lessee, Lease, Option to Extend, Maximum Term (Year)	5 years
Lessee, Lease, Option to Terminate, Term (Year)	1 year
Minimum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	1 year
Maximum [Member]
Lessee, Lease, Remaining Term of Contract (Year)	4 years

Note O - Leases - Lease Cost (D

Note O - Leases - Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Amortization of right-of-use assets	$ 129	$ 129
Interest on lease liabilities	2	9
Total finance lease cost	131	138
Operating lease cost	418	365
Short-term lease cost	210	199
Variable lease cost	39	47
Less: sublease income	(157)	(91)
Total lease costs	$ 641	$ 658

Note O - Leases - Supplement Ca

Note O - Leases - Supplement Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating cash flows from finance leases	$ 2	$ 9
Financing cash flows from finance leases	16	173
Operating cash flows from operating leases	522	460
Operating cash flows from short-term leases	210	199
Operating cash flows from variable lease costs	39	47
Finance leases	0	0
Operating leases	$ 123	$ 0

Note O - Leases - Supplement Ba

Note O - Leases - Supplement Balance Sheet Information Related to Lease (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
less: accumulated depreciation and amortization	$ (1,443)	$ (1,925)
Lease liabilities, finance leases	6	21
Operating lease right-of-use assets	988	1,141
Total operating lease right-of-use assets	988	1,141
Current portion of operating lease liabilities	480	356
Operating lease liabilities, less current portion	843	1,232
Total operating lease liabilities	$ 1,323	$ 1,588
Finance leases (Year)	1 year	1 year
Operating leases (Year)	3 years	4 years
Finance leases	14.30%	12%
Operating leases	7.30%	7.50%
Property and Equipment, At Cost [Member]
Property and equipment, at cost	$ 1,031	$ 1,031
Accumulated Depreciation and Amortization [Member]
less: accumulated depreciation and amortization	(780)	(651)
Property and Equipment, Net [Member]
Property and equipment, net	251	380
Other Current Liabilities [Member]
Other current liabilities	6	15
Other Noncurrent Liabilities [Member]
Other long-term liabilities	0	6
Operating Lease Right-of-Use Assets [Member]
Operating lease right-of-use assets	988	1,141
Total operating lease right-of-use assets	988	1,141
Current Portion of Operating Lease Liabilities [Member]
Current portion of operating lease liabilities	480	356
Operating Lease Liabilities, Less Current Portion [Member]
Operating lease liabilities, less current portion	$ 843	$ 1,232

Note O - Leases - Maturities of

Note O - Leases - Maturities of lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
2023, finance leases	$ 7
2023, operating leases	563
2024, finance leases	0
2024, operating leases	488
2025, finance leases	0
2025, operating leases	389
2026, finance leases	0
2026, operating leases	30
2027, finance leases	0
2027, operating leases	0
Thereafter, finance leases	0
Thereafter, operating leases	0
Total lease payments, finance leases	7
Total lease payments, operating leases	1,470
Less: future interest expense, finance leases	(1)
Less: future interest expense, operating leases	(147)
Lease liabilities, finance leases	6	$ 21
Lease liabilities, operating leases	$ 1,323	$ 1,588

Note P - Employee Benefit Plan

Note P - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Retirement Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 197,000	$ 164,000
Profit Sharing Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0
Defined Contribution Plan, Requisite Service Period (Year)	3 years

Note Q - Significant Events (De

Note Q - Significant Events (Details Textual)			12 Months Ended
	Jan. 09, 2023 shares	Jan. 06, 2023 USD ($) shares	Dec. 31, 2022 shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			1,434,245
Chief Executive Officer [Member] | 2014 Equity Incentive Plan [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	700,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Number of Installments	4
Company's President and Former Chief Executive Officer [Member] | Subsequent Event [Member]
Transition Agreement, Continued Payment of Base Salary, Period (Month)		18 months
Transition Agreement, Continued Medical, Dental and Vision Coverage, Period (Month)		18 months
Transition Agreement, Monthly Consulting Fees | $		$ 40,000
Company's President and Former Chief Executive Officer [Member] | Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		547,945